Article: Introgen announces that INGN-241 cancer therapy triggers immune system to kill cancer cells: GDVI, NTIQ, BAX, INGN.

Article: InvestSource Technical Alerts: ELIN, ADBE, QCBC, NGAS, ...
M2 Presswire;  March 19, 2004 ;     700+ words ... ... PRESSWIRE-19 March 2004-InvestSource Inc.: InvestSource Technical Alerts: ELIN, ADBE, QCBC, NGAS, INGN(C)1994-2004 M2 ... Incorporated (Nasdaq: INGN) up 9% as they withdraw ... the Alerts On! ABOUT InvestSource: InvestSource is an ...

Article: InvestSource ALERT: WLFI, AVCI, MSFT, ETS, INGN.
M2 Presswire;  March 23, 2004 ;     700+ words ... ... PRESSWIRE-23 March 2004-InvestSource Inc.: InvestSource ALERT: WLFI, AVCI, MSFT, ETS, INGN(C)1994-2004 M2 ... Incorporated (NASDAQ: INGN) announced the withdrawal ... the Alerts On! ABOUT InvestSource: InvestSource is an ...

Article: INGN 241 may work effectively as radiation sensitizer to ...
Biotech Week;  May 8, 2002 ;     700+ words ... ... Introgen Therapeutics, Inc., (INGN) recently presented data from three preclinical studies showing that INGN 241, its mda-7 gene therapy product ... also suggests that the combination of INGN 241 and conventional radiation therapy ...

Article: Introgen's INGN 241 in Combination With Tarceva Inhibits ...
PR Newswire;  June 4, 2006 ;     700+ words ... ... show that the combination of Introgen's INGN 241 and Tarceva(R) (erlotinib HCl ... Meeting (ASGT), held May 31-June 4. INGN 241 is a targeted molecular therapy currently ... the combination of an EGFR inhibitor with INGN 241 resulted in greater inhibition of EGFR ...

Article: Introgen's INGN 241 Drug Provides Multiple Routes to ...
PR Newswire;  July 16, 2003 ;     700+ words ... ... the gene that is the active component in INGN 241, kills a broad array of cancer cells ... the multiple cancer killing activities of INGN 241 related to its anti-angiogenic and ... for the treatment of several cancers. INGN 241 is currently undergoing phase 1 and ...

Article: Preclinical Studies With Introgen's INGN 241 Cancer Drug ...
PR Newswire;  April 15, 2003 ;     700+ words ... ... Introgen's mda-7 based cancer drug, INGN 241 have been published in the 2003 Proceedings ... potent mda-7 gene works against cancer. INGN 241 is also the subject of an ongoing phase ... research and development at Introgen. "INGN 241 works to kill tumor cells directly ...

Article: Drug Candidate INGN 201 Looks Promising.
Gene Therapy Weekly;  January 17, 2002 ;     700+ words ... ... data for its p53 gene drug candidate, INGN 201, adenoviral-p53 at the 10th International ... further evidence in support of the use of INGN 201 in the treatment of cancer. Lou Zumstein ... and nontoxic vector. We cannot detect INGN 201 adenovirus integrating into genomic ...